Sabinsa reaches IP milestone with 300-plus ingredient patents granted

Most recently, patents were awarded in Australia, Canada, Europe, and the U.S.

Sabinsa (East Windsor, NJ) announced a milestone in its ongoing intellectual property mission. The company says it now holds 308 separate patents across the world for its ingredients. Most recently, patents were awarded in Australia, Canada, Europe, and the U.S. The patents cover composition, use, and process, including for the company’s newest ingredients Nigellin and Sabroxy.

The recent patents include a patent for the company’s ingredient Nigellin, a Nigella sativa (black cumin seed) ingredient composition rich in thymoquinone and thymohydroquinone. The U.S. patent applies to decreasing blood glucose levels (US10881623).

In addition, Sabroxy, a proprietary, patented Oroxylum indicum cognitive-health ingredient composition standardized for oroxylin A, baicalein, and chrysin, gained a U.S. patent this year for managing and alleviating symptoms of neurotoxicity due to hyperglycemia and chemotherapeutics (US10894029) as well as a U.S. patent for decreasing blood triglyceride levels (US10959980) and a patent that is pending for reducing epileptic seizures.

The company’s proprietary probiotic ingredient LactoSpore (Bacillus coagulans MTCC 5856) gained U.S. patents late last year for inhibiting infections related to H. pylori that can contribute to gastritis (US10792295) and for reducing intestinal gas and inhibiting gas-producing microbes (US10806760).

Finally, the company’s LactoSporin ingredient, which is a trademarked, extracellular metabolite of its LactoSpore probiotic, gained a U.S. patent this year for preventing the formation of aging signs on the skin (US10966919).